Veoza as NICE Recommends: An NHS Inflection Point for Menopausal Care
veoza, a non-hormonal pill also known as fezolinetant, is now available on the NHS in England when hormone replacement therapy (HRT) is unsuitable, creating a clear inflection in options for menopausal symptom management.
What Happens When Veoza Is Offered on the NHS?
The National Institute for Health and Care Excellence (NICE) has recommended the use of fezolinetant for moderate to severe hot flushes and night sweats, expanding treatment choices beyond hormonal approaches. The daily pill works by blocking nerve pathways in the brain that trigger vasomotor symptoms. Helen Knight, director of medicines evaluation at the National Institute for Health and Care Excellence, said the evidence shows fezolinetant can meaningfully reduce symptoms and was found to be cost effective. Around 500, 000 women in England could benefit, particularly those who cannot use HRT because of underlying health conditions.
What If HRT Remains the First-Line Treatment?
HRT is still identified as the first-line treatment because of its established benefits and the variety of formulations available. That position shapes how Veoza will be used in practice: as an important alternative rather than a wholesale replacement. The practical implications for clinicians and patients can be framed in a compact comparison:
- HRT: First-line therapy; available in tablets, patches and gels; established benefit profile.
- Veoza (fezolinetant): Non-hormonal, taken once daily; blocks brain nerve pathways that trigger hot flushes and night sweats; assessed by NICE as cost effective for those unable or unwilling to take HRT.
- Access and eligibility: NICE recommendation applies in England, with Wales and Northern Ireland often following NICE guidance and Scotland operating its own decision body.
What Should Patients and Clinicians Expect Next?
Clinicians will continue to present HRT as the standard option but can now offer a licensed non-hormonal alternative for those with contraindications or personal preference. Dr Sue Mann, national clinical director in women’s health for NHS England, described the recommendation as welcome for women who are unable to or do not wish to take HRT and said it could help hundreds of thousands manage their symptoms more effectively. The drug was approved for use previously and has now been recommended by NICE for NHS prescription for moderate to severe vasomotor symptoms; the manufacturer is Astellas Pharma. Implementation will involve updating prescribing pathways, informing eligible patients, and monitoring outcomes and safety in routine practice. Readers should expect practical roll-out through standard NHS channels and clinicians to outline how this option differs from hormonal therapy, especially for those with a history that makes HRT unsuitable. The change is an important step in expanding care choices for people experiencing menopausal hot flushes and night sweats, and it reframes how clinicians approach treatment discussions about veoza
